Countries World
Glenmark Launches Generic Sugammadex Injection in the US
Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch1 of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL)...
July 30, 2026 | News
8 APAC Assets That Went Global The Out-Licensing Class of 2025 to 2026
Business development teams across the region keep arriving at the same question, phrased slightly differently each time. What did a comparable asset, at a ...
July 29, 2026 | Analysis
Waters Launches Next-Generation IVD Mass Spectrometer for High-Sensitivity Clinical Diagnostics
Brings Xevo™ TQ Absolute XR Mass Spectrometer's industry-leading tandem quadrupole MS sensitivity to clinical applications across women's health, c...
July 29, 2026 | News
HoneyNaps Expands Global CRO Services with AI-Powered Sleep Analytics Platform
Strengthens specialized AI-powered sleep data analysis services for global pharmaceutical, medical device, and healthcare companies Targets the rapidly ...
July 29, 2026 | News
Stopped: The Six-Year Cost of Trials That Never Reached the Finish Line
One infusion, no programme A gene therapy is a one-way door. The vector goes in once, it cannot be taken out, and with current adeno-associated virus tech...
July 28, 2026 | Analysis
Biointron Launches RushData to Accelerate AI-Driven Antibody Discovery with High-Throughput Experimental Validation
1-day CHO expression for data generation in days, not weeks, for standardized, structured datasets ready for AI/ML-driven design Custom workflows for ...
July 28, 2026 | News
Harbour BioMed Forecasts Record H1 2026 Profit as Strategic Partnerships Drive Growth
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutic...
July 27, 2026 | Company results
Nova Biomedical Expands Cell Line Development Portfolio with NanoCellect Technology Acquisition
Nova Biomedical announced a transaction involving certain assets of NanoCellect, a provider of microfluidic cell sorting technology. This expands Nova Bio...
July 27, 2026 | News
Nona Biosciences Partners with MedUni Vienna to Advance Fully Human Antibody Research
Partnership grants Ignaz Semmelweis Institute access to Nona's H2L2 Harbour Mice® transgenic mouse technology platform for translational antibody ...
July 24, 2026 | News
Discount or Validation? Western Pharma’s Appetite for Chinese Assets
There is a number that has stopped being a niche statistic for Asia-watchers and started reshaping where the global drug industry shops. The average upfron...
July 24, 2026 | Analysis
Lonza and Engitix Partner to Advance Next-Generation ECM-Targeted ADCs
Lonza grants Engitix target-specific license for GlycoConnect®, HydraSpace® and SYNtecan E™ linker-payload technologies for ADC de...
July 22, 2026 | News
Lundbeck Completes Patient Randomisation in Phase III Bexicaserin Trial for Rare Epilepsies
DEEp OCEAN is a global trial designed to evaluate the investigational molecule bexicaserin for the treatment of seizures associated with DEEs, a diverse ...
July 22, 2026 | News
Vector Partners with Caresyntax to Build Real-World Evidence Programme for Opioid-Sparing Surgical Platform
Caresyntax will design and operate a multi-phase real-world evidence program for Vector, culminating in a prospective comparative reg...
July 21, 2026 | News
Samsung Biologics Launches CHF 1.46B All-Cash Bid to Acquire PolyPeptide
Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding therefrom any treasury share...
July 21, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
